Repligen (RGEN) Stock Looks Reasonable Despite Its 35% Five Year Fall

Repligen has seen mixed share-price results over different time frames, with a gain over the past year but a decline over five years. This puts the spotlight squarely on whether the current US$178.27 price is aligned with what its cash flows can support. With fresh financing activity and business updates on the table, the key issue for you is whether the stock price fairly reflects the cash it is expected to generate over time.

• Over the past five years the stock has fallen 34.7%. This raises the question of whether the market has been reassessing the value of Repligen's future cash generation or simply its risk profile.
• The new US$1b issue of low-coupon convertible notes and planned use of funds for share repurchases, working capital and potential acquisitions can affect both future cash outflows and how much of those cash flows accrue to existing shareholders.
• What if you looked at Repligen through its sales instead? See why Repligen's 14.1x P/S tells a different valuation story.

The issue now is whether Repligen's current market value is supported by the intrinsic value suggested by a Discounted Cash Flow (DCF) view of its cash flows.

Repligen is only one way to frame this cash flow question, and a focused stock screen built around 35 high quality undervalued stocks.

Where Does Repligen Sit on Cash Flow?

The Discounted Cash Flow (DCF) model here looks at the cash Repligen could return to shareholders over time and adjusts those amounts back to today. On this view, the stock’s estimated intrinsic value appears broadly in line with the current US$178.27 share price. The latest twelve month free cash flow is about US$97.6m, so the framework already assumes a meaningful ramp up in future cash generation over the coming years.

In the projection set, free cash flow is treated as growing from that base rather than shrinking. This places emphasis on Repligen converting its current product mix and pipeline into steadily larger cash surpluses. Repligen’s recent US$1.0b issue of low coupon convertible senior notes, with part of the proceeds earmarked for share repurchases and acquisitions, fits this picture because it can lift per share cash flow if deployed carefully while keeping explicit interest costs low. The DCF projections put Repligen's estimated intrinsic value broadly in line with the current share price, so the market price already reflects this growth path. Find out what Repligen could be worth using our Discounted Cash Flow (DCF) estimate.

The Repligen Narrative: What Would Justify Today's Price?

Narratives for Repligen pick up where a single DCF output leaves off and explain which paths for growth, margins and earnings would need to occur for the stock to be worth materially more or less than today’s price, based on scenarios you can monitor over time. Instead of only seeing one valuation number, you see the future business conditions that number relies on and can judge for yourself whether they are unfolding.

Repligen draws a split crowd, with one camp seeing more upside in the current setup and another arguing expectations already look full.

Bull case: 11% undervalued

"Analysts lifted their fair value estimate for Repligen to $199.70 from $194.95, citing refreshed price targets that now run as high as $225…"

Discover why this Narrative puts Repligen at 11% undervalued.

Bear case: 11% overvalued

"Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high…"

Explore why this Narrative puts Repligen at 11% overvalued.

One more Repligen check that belongs beside the valuation work

Price and cash flows tell only part of the story for Repligen, because the people steering the business and how their rewards line up with your interests can tilt outcomes in quiet but powerful ways. See who runs Repligen and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com